Institution Directory

Clinical trials at University of Colorado Anschutz

Sites in Aurora, CO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 3:42 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1008

Shown on this page

Current sort

Live official records

Conditions: Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
Interventions: Thoracic, Abdominal, Custom Device, Illiac Artery; Device
Lead sponsor: Vascutek Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 17
States / cities: Long Beach, California • Aurora, Colorado • Colorado Springs, Colorado + 14 more

Conditions: Astrocytoma, Oligodendroglioma
Interventions: Vorasidenib, Pembrolizumab; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: Germ Cell Tumor, Metachronous Malignant Neoplasm, Seminoma, Stage I Testicular Cancer AJCC v8, Stage IA Testicular Cancer AJCC v8, Stage IB Testicular Cancer AJCC v8, Stage IS Testicular Cancer AJCC v8
Interventions: Biomarker Analysis, Blood Product Collection; Other · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 956 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 412
States / cities: Gilbert, Arizona • Kingman, Arizona • Tucson, Arizona + 261 more

Conditions: Locally Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma
Interventions: Losartan, Pembrolizumab, Stereotactic Body Radiation Therapy; Drug · Biological · Radiation
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Sacramento, California • Aurora, Colorado

Conditions: Stroke, Patent Foramen Ovale
Interventions: AMPLATZER™ PFO Occluder; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 1,214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 78
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 63 more

Conditions: Acute Lymphoid Leukemia, Acute Lymphoblastic Leukemia
Interventions: CD19 Directed CAR T Cell; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Select Advanced Solid Tumors
Interventions: Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors; Drug
Lead sponsor: Immunocore Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 22
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 17 more

Conditions: Breast Cancer
Interventions: Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost, Sequential boost; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 2,354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 386
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 304 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Semaglutide Pen Injector, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: HIV Treatment, HIV Prevention
Interventions: At Home Self-Collections; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Obesity
Interventions: Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 33
States / cities: Santa Ana, California • Aurora, Colorado • Hamden, Connecticut + 30 more

Conditions: Cancer
Interventions: Antibody-Drug Conjugate; Drug
Lead sponsor: MBrace Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 17
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 13 more

About this University of Colorado Anschutz institution page

What this page lists: ClinicalTrials.gov records that list University of Colorado Anschutz in Aurora, CO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at University of Colorado Anschutz

Filter and sort this campus

Live official records

Terumo Aortic Global Endovascular Registry

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

A Study of miRNA 371 in Patients With Germ Cell Tumors

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

AMPLATZER PFO Occluder Post Approval Study

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

About this University of Colorado Anschutz institution page